跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 26,129 条关于
“Enhanced Liver Fibrosis”
全部
26,129
临床试验
17,514
药物
619
机构
66
资讯
7,930
去年
Semaglutide 2.4 mg Shows Promise in MASH Treatment: Phase 3 ESSENCE Trial Results
去年
Sagimet's Denifanstat Shows Significant Anti-Fibrotic Benefits in Advanced MASH Patients at AASLD 2025
去年
Ipsen's Iqirvo (elafibranor) Shows Sustained Efficacy and Safety in Long-Term PBC Treatment
去年
Advanced Liver Cancer Market to Reach $11.13 Billion by 2035, Driven by Early Detection and Novel Therapies
去年
Iqirvo (Elafibranor) Shows Sustained Efficacy and Safety in Long-Term PBC Treatment
10个月前
Galectin Therapeutics' Belapectin Shows Sustained Antifibrotic Effects in MASH Cirrhosis Through 36 Months
去年
D&D Pharmatech's DD01 Shows Rapid Liver Fat Reduction in MASH Phase 2 Trial, Matching Competitor Results in Quarter of the Time
去年
Ipsen's Elafibranor Shows Promise in Phase II Trial for Primary Sclerosing Cholangitis
去年
Leronlimab Shows Promising Results in Reversing Liver Fibrosis, CytoDyn Reports
去年
HistoIndex Launches AI-Powered FibroSIGHT Plus for Enhanced MASH Fibrosis Assessment
第 1 页,共 793 页
上一页
下一页